Kura Oncology获得Wedbush和Cantor Fitzgerald的“跑赢大盘”和“增持”评级。 Kura Oncology receives "outperform" and "overweight" ratings from Wedbush and Cantor Fitzgerald.

Kura Oncology （KURA）获得了Wedbush的“跑赢大盘”评级，并获得了Cantor Fitzgerald的“增持”评级。 Kura Oncology (KURA) has received an "outperform" rating from Wedbush and a reaffirmed "overweight" rating from Cantor Fitzgerald. 生物技术公司的重点是发展各种癌症的治疗方法。 The biotech company focuses on developing treatments for various cancers. 两个金融机构都对库拉肿瘤学的未来前景表示乐观。 Both financial institutions express optimism about Kura Oncology's future prospects.